The Pharmaceutical Industry has seen a big transformation over the past few decades. The Regulations are becoming more and more stringent with the evolvement of science related to analysis of the safety for pharmaceuticals. The availability of the validated targets for the new research is being downsized. All these factors has have led to shrinking of the discovery pipelines that has in turn, created a need to look into alternative means for increasing business, like devising combination products. The development of a combination of innovative forms of the products to sustain business poses additional compliance issues and an assessment is needed to decide what data could be grandfathered and what are the areas of remediation.